Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
After Arrowhead Pharmaceuticals cleared out its work on a clinical-stage cardiovascular candidate, the company is filling the blank space with two obesity assets, both set to enter the clinic in early 2025.
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
With two cardiovascular disease candidates in or near phase 3, RNAi specialist Arrowhead Pharmaceuticals has dropped one prospect and thrown its weight behind the other to manage its spending.
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome